TH-SC01
Phase 1Small molecule
TH-SC01 is one of 21 small molecule programs targeting Anal fistula. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Anal Fistula
#DrugCompanyPhaseTrials
1Humira
CCelltrion
Approved
Cipro
BayerPhase 3
Darvadstrocel
TakedaApproved
Micronized Purified Flavonoid Fraction
TTanta University
Approved
Rinvoq
AbbViePhase 1
Visilizumab
FFacet Biotech
Phase 2
Exoflo
DDirect Biologics, LLC
Phase 2
Rhpdgf-BB
LLynch Biologics LLC
Phase 2
Acanya
PfizerPreclinical
Mesenchymal Stem Cells
JJiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TH-SC01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- JJinling Hospital, China